Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

This weekend, the FDA released its recommendation for Novavax, a vaccine designed to combat COVID-19. That in itself is not ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...